Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. (NYSE: PHG) is a global leader in health technology focused on improving lives through meaningful innovation. This news hub provides investors and healthcare professionals with centralized access to official press releases and verified updates about Philips' advancements in diagnostic imaging, connected care systems, and personal health solutions.
Discover timely information on product launches, regulatory milestones, and strategic partnerships that shape Philips' position in the healthcare sector. Our curated collection includes earnings reports, technology innovations, and market expansion announcements – all essential for understanding the company's trajectory in medical equipment and digital health solutions.
Key updates cover developments in AI-driven diagnostic tools, telehealth platforms, and sustainable healthcare initiatives. Bookmark this page to stay informed about Philips' progress in addressing critical challenges across radiology, cardiology, and home-based patient care through its integrated health technology ecosystem.
Royal Philips announces the launch of the QuickClear Mechanical Thrombectomy System, a single-use, all-in-one catheter and pump designed for removing blood clots from peripheral vessels. This system simplifies procedures, eliminating the need for capital equipment, and features a compact design with high aspiration power. Recently cleared by the U.S. FDA, the system aims to provide cost-effective solutions in both hospital and outpatient settings. Philips plans further geographical expansion for this innovative device, enhancing its vascular treatment portfolio.
Royal Philips (NYSE: PHG) has established a seven-year strategic partnership with Tampa General Hospital to enhance technological capabilities at the hospital. This partnership provides TGH with early access to Philips' innovations aimed at improving patient care and operational efficiency, enabling cost-effective solutions. Philips will deliver new software packages, healthcare informatics, and replace bedside monitors across the 1,006-bed facility. This agreement underscores TGH's commitment to innovation and quality healthcare during challenging times, as highlighted by its proactive technology replacement planning.
Philips has launched the Azurion Lung Edition, an advanced imaging platform for lung cancer diagnosis and treatment. This system combines Cone Beam CT with X-ray guidance, enabling clinicians to perform minimally invasive procedures in a single room. Lung cancer causes 1.7 million deaths annually, with over 60% diagnosed late. The Azurion Lung Edition aims to offer timely diagnosis and treatment, potentially enhancing patient outcomes and lowering costs. Currently available in the U.S., this innovative technology is expected to significantly impact lung cancer care.
New analysis shows a potential 50% decrease in air pollution around schools in the UK and Ireland could lead to up to a 20-50% reduction in children with poor lung function. Launched by Royal Philips and the Philips Foundation alongside Global Action Plan, the Clean Air for Schools Framework aims to guide schools in addressing air quality issues. The initiative follows findings that reduced pollution during lockdown led to a significant decline in children's asthma exacerbations. The framework provides tailored action plans to help schools improve air quality.
On September 14, 2020, Royal Philips (NYSE: PHG) announced ambitious Environmental, Social, and Corporate Governance (ESG) commitments for 2025, building on its previous 'Healthy people, Sustainable planet' program. Philips aims for 100% EcoDesign in new products, improve the lives of 2 billion people annually, and achieve CO2 neutrality in operations. Key targets include sourcing 75% renewable energy and increasing circular economy revenues from 15% to 25%. The company also emphasizes transparency in tax contributions and plans to improve labor conditions within its supply chain.
Royal Philips (NYSE: PHG) released its Future Health Index Insights survey focusing on younger healthcare professionals during COVID-19. Key findings include:
- 61% of younger doctors preferred telehealth over AI (53%) as the most impactful technology during the pandemic.
- 47% reported increased appreciation from patients, while 44% noted improved collaboration with colleagues.
- Only 9% are likely to leave the profession, with 38% more committed to staying in medicine.
On September 2, 2020, Royal Philips (NYSE: PHG) showcased innovations at its virtual consumer health event, emphasizing the shift towards "health-at-home" solutions fueled by the COVID-19 pandemic. CEO Frans van Houten noted an increasing focus on preventative care and digital healthcare services. Philips introduced connected health solutions enabling users to monitor their health and engage with caregivers remotely. Innovations include teledentistry services and apps for expectant parents. These developments not only address consumer needs but also reflect a strategic pivot in Philips' health technology offerings.
Royal Philips (NYSE: PHG) announced the next-generation Azurion image-guided therapy platform, enhancing clinical and operational lab performance. This platform integrates imaging, physiology, hemodynamic, and informatics applications for improved clinician control during procedures. It features SmartCT, allowing 3D CT-like image acquisition and visualization. With over two million procedures performed since its launch, Azurion helps streamline workflows, improve decision-making, and optimize patient care. The platform is available in three versions, catering to specific customer needs.
Royal Philips (NYSE: PHG) announced a partial termination of its ventilator contract with the U.S. Department of Health and Human Services (HHS), reducing the original order of 43,000 ventilators by 30,700 units. Philips has successfully delivered 12,300 ventilator configurations to the Strategic National Stockpile by the end of August 2020. CEO Frans van Houten stated that while the reduction will impact financial performance, the company expects to achieve modest sales growth and an Adjusted EBITA margin comparable to last year by year's end.
Philips has launched the Affiniti CVx and released version 7.0 of its EPIQ CVx ultrasound systems at ESC 2020. These advancements aim to enhance productivity in cardiology departments amid rising patient volumes linked to cardiac diseases. Key features include a streamlined workflow for cardiologists, AutoStrain technology that delivers a 70% reduction in analysis time, and various automated tools for improved diagnostic confidence. The Affiniti CVx has not yet received a CE mark for EU marketing.
